Sectors: Pharmaceuticals
Industries: Medical research
Imperial College London has licensed a new cell therapy technology to Australian company SUDA Pharmaceuticals.
The technology, developed by Professor Tassos Karadimitrus and his team at Imperial’s Centre for Haematology, is based on the invariant natural killer T (iNKT) cell, a rare immune cell.
You can read more about the technology, and the license deal, in this longform article by Dr David Silverman.
A cytokine that promotes wound healing by accelerating re-epithelialization of the wound bed faster than FDA approved products. The treatment also has a potential to minimise scarring after injury. Find out more
Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots. Find out more
A fully flexible, scalable and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific sequences along the backbone of a double-stranded DNA carrier. Find out more
The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim. Find out more
Imperial will benefit from continued support for translational biomedical research under a unique technology transfer model. Find out more
Imperial has licensed iNKT cell technology based on research by Prof. Tassos Karadimitris to SUDA Pharmaceuticals. Find out more
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Sign up for monthly technology alerts via email, and find other ways to connect with us.
